Summarized by Masters of Longevity from Longevity Technology.
This article previews a biotech trial story about an oral drug from aging-research that’s being tested for treating diabetic eye disease, inviting readers curious about how longevity science translates into clinical trials.
Key Takeaways
- BioAge has dosed the first participant in QUELL-DME, a Phase 2 trial of oral BGE-102 for diabetic macular edema.
- The randomized three-arm trial will compare anti-VEGF plus placebo, anti-VEGF plus 90 mg BGE-102 daily, and sham injection plus 90 mg BGE-102 daily.
- BGE-102 targets NLRP3, was identified via human aging cohort analysis, and earlier studies showed reductions in hsCRP levels.
